Janus Henderson Group PLC Sells 146,139 Shares of Progyny, Inc. (NASDAQ:PGNY)

Janus Henderson Group PLC trimmed its stake in Progyny, Inc. (NASDAQ:PGNY) by 29.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 343,238 shares of the company’s stock after selling 146,139 shares during the quarter. Janus Henderson Group PLC’s holdings in Progyny were worth $5,922,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PGNY. Signaturefd LLC lifted its holdings in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after buying an additional 1,526 shares during the last quarter. Caitlin John LLC raised its holdings in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock worth $57,000 after buying an additional 3,183 shares during the last quarter. Natixis bought a new position in shares of Progyny in the fourth quarter valued at $69,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Progyny during the fourth quarter valued at about $74,000. 94.93% of the stock is owned by institutional investors.

Progyny Trading Up 1.6%

Shares of Progyny stock opened at $22.30 on Monday. The business’s fifty day simple moving average is $22.08 and its 200 day simple moving average is $19.79. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $30.42. The firm has a market capitalization of $1.91 billion, a P/E ratio of 38.45, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million during the quarter, compared to analysts’ expectations of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period last year, the firm posted $0.17 earnings per share. Analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PGNY. JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Canaccord Genuity Group dropped their target price on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Finally, Bank of America upped their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $23.45.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.